| 中文名称: | DAMGO | ||||
|---|---|---|---|---|---|
| 英文名称: | DAMGO | ||||
| 别名: | Tyr-D-Ala-Gly-MePhe-Gly-ol | ||||
| CAS No: | 78123-71-4 | 分子式: | C26H35N5O6 | 分子量: | 513.59 |
| CAS No: | 78123-71-4 | ||||
| 分子式: | C26H35N5O6 | ||||
| 分子量: | 513.59 | ||||
基本信息
|
产品编号： |
D11500 |
||||
|
产品名称： |
DAMGO |
||||
|
CAS: |
78123-71-4 |
储存条件 |
粉末 |
-20℃ |
四年 |
|
|
|
||||
|
分子式： |
溶于液体 |
-80℃ |
两年 |
||
|
分子量 |
513.59 |
-20℃ |
一个月 |
||
|
化学名： |
Tyr-D-Ala-Gly-MePhe-Gly-ol |
||||
|
Solubility (25°C)： |
|||||
|
体外:
|
DMSO |
100mg/mL (194.7mM) |
|||
|
Ethanol |
100mg/mL (194.7mM) |
||||
|
Water |
100mg/mL (194.7mM) |
||||
|
体内(现配现用): |
1.请依序添加每种溶剂：10% DMSO→40% PEG300→5% Tween-80→45% saline Solubility: ≥ 2.5mg/mL (4.87mM); Clear solution |
||||
|
此⽅案可获得 ≥ 2.5mg/mL (4.87mM，饱和度未知) 的澄清溶液。 以 1mL ⼯作液为例，取 100μL 25.0mg/mL 的澄清 DMSO 储备液加到 400μL PEG300 中，混合均匀；向上述体系中加⼊ 50μL Tween-80，混合均匀；然后继续加⼊ 450μL ⽣理盐⽔定容⾄ 1mL。 |
|||||
|
2.请依序添加每种溶剂：10% DMSO→90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5mg/mL (4.87mM); Clear solution |
|||||
|
此⽅案可获得 ≥ 2.5mg/mL (4.87mM，饱和度未知) 的澄清溶液。 以 1mL ⼯作液为例，取 100μL 25.0mg/mL 的澄清 DMSO 储备液加到 900μL 20% 的 SBE-β-CD ⽣理盐⽔⽔溶液中，混合均匀。 |
|||||
|
3.请依序添加每种溶剂：10% DMSO→90% corn oil Solubility: ≥ 2.5mg/mL (4.87mM); Clear solution |
|||||
|
此⽅案可获得 ≥ 2.5mg/mL (4.87mM，饱和度未知) 的澄清溶液，此⽅案不适⽤于实验周期在半个⽉以上的实验。 以 1mL ⼯作液为例，取 100μL 25.0mg/mL 的澄清 DMSO 储备液加到 900μL ⽟⽶油中，混合均匀。 |
|||||
|
＜1mg/ml表示微溶或不溶。 |
|||||
|
普西唐提供的所有化合物浓度为内部测试所得，实际溶液度可能与公布值有所偏差，属于正常的批间细微差异现象。 |
|||||
|
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；⼀旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 |
|||||
制备储备液
|
浓度
溶液体积 质量 |
1mg |
5mg |
10mg |
|
1mM |
1.9471mL |
9.7354mL |
19.4708mL |
|
5mM |
0.3894mL |
1.9471mL |
3.8942mL |
|
10mM |
0.1947mL |
0.9735mL |
1.9471mL |
|
50mM |
0.0389mL |
0.1947mL |
0.3894mL |
生物活性
|
产品描述 |
一种选择性的 μ-阿片受体 (μ-OPR) 激动剂，Kd 值为 3.46nM。 |
|
靶点 |
μ opioid receptor 17nM(ki) |
|
体外研究 |
DAMGO, a μ-opioid receptor selective agonist, distinguishes between μ- and δ-opioid receptors around their first extracellular loops. In native μ-OPR, the Kd value for DAMGO is 3.46± 0.84nM (n=3). The chimeric receptormMDD, in which the carboxy-terminal half of μ-OPR is replaced with the corresponding region of δ-OPR, exhibits an equivalent affinity (Kd =2.13±0.40nM; n=3) to DAMGO compared with the native μ-OPR. DAMGO is a selective μ-opioid peptide. DAMGO abolishes the neuroprotective effect of CXCL12 in N-methyl-d-aspartate (NMDA) neurotoxicity studies. Regulation of neuronal response to CXCL12 is essential for shaping of developing and mature central nervous system (CNS). To establish whether DAMGO alter the effect of CXCL12 on neuronal survival, the ability of CXCL12 to protect neurons from N-methyl-d-aspartate (NMDA)-induced death is examined in the presence and absence of DAMGO. Cortical cultures are treated with DAMGO (1 and 10μM). Neurons are subsequently exposed tonMDA (20 min) and/or CXCL12 (added 10 min beforenMDA) in the absence of glia and then returned to the original culture dishes with the glial feeder layer. Neuronal death is evaluated after 24 h. DAMGO inhibits neuronal survival promoted by CXCL12. |
推荐实验方法(仅供参考)
|
Cell Assay |
Neurons (9 days in vitro) are treated with DAMGO (10μM) for 24 h in their original culture dish, subsequently transferred to a dish containingmg2+-free saline with glycine (15μM), and exposed tonMDA (100μM) and/or CXCL12 (20nM) in absence of glia. After treatments, neurons are moved back into the original culture dishes containing glia. Neuronal death is evaluated after 24 h. Hoechst 33342 (3μg/mL) combined with cleaved caspase-3 (1:100) staining is used to identify normal and apoptotic cells |
本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为：
质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)
摩尔浓度计算公式
用本工具协助配置特定浓度的溶液，使用的计算公式为：
开始浓度 x 开始体积 = 最终浓度 x 最终体积
稀释公式
稀释公式一般简略地表示为：C1V1 = C2V2 ( 输入 输出 )
